On January 14, Shanghai Kaikai Industry Company Limited(600272) rose strongly again. In the last 10 trading days, Shanghai Kaikai Industry Company Limited(600272) harvested 9 daily limit boards, with a cumulative increase of 1.2 times.
That night, the Shanghai Stock Exchange issued a market transaction supervision report, saying that it would focus on monitoring the stocks with serious abnormal fluctuations such as Shanghai Kaikai Industry Company Limited(600272) .
stock price changes are mainly monitored by the exchange
On January 14, Shanghai Kaikai Industry Company Limited(600272) continued to make an upward attack after the opening and closed the trading limit in the afternoon. As of the closing, Shanghai Kaikai Industry Company Limited(600272) reported 16.5 yuan / share, with the latest market value of 4 billion yuan. On January 14, Shanghai Kaikai Industry Company Limited(600272) turnover rate was 29.84%, while the actual turnover rate calculated according to free tradable shares was as high as 49.95%.
On the same day, the Shanghai Stock Exchange issued a market trading supervision report, announcing the key monitoring of Shanghai Kaikai Industry Company Limited(600272) and other seriously abnormal fluctuation stocks.
According to the data of China Securities Taurus app, the stock price trend of Shanghai Kaikai Industry Company Limited(600272) in 2021 is calm, basically hovering below 7 yuan, and the transaction is also very light. However, since the last trading day in 2021, Shanghai Kaikai Industry Company Limited(600272) 10 day 9 board has increased by 1.21 times.
It is worth noting that on January 13, Shanghai Kaikai Industry Company Limited(600272) suddenly exploded and dived at the end of the trading day, suddenly falling by 16 percentage points, which frightened many investors. If you buy on the daily limit, you will lose about 15% on that day.
Before that, Shanghai Kaikai Industry Company Limited(600272) on January 7, it also walked out of the trend of “Earth Sky plate”.
the company prompts investment risks
According to public information, Shanghai Kaikai Industry Company Limited(600272) main business includes circulation of traditional Chinese medicine, traditional Chinese medicine service (TCM consultation service) and garment production and sales. Among them, the pharmaceutical industry is mainly the wholesale and retail of Chinese and Western patent medicines, the pharmaceutical care of traditional Chinese medicine with the Chinese time-honored brand “leiyunshang” as the brand, and the sales of high-grade tonics of its own brand “shanglei”; The garment industry is mainly engaged in the production, wholesale and retail of “Kaikai” brand shirts and sweaters and Kaikai brand clothing series.
In the secondary market, the recent intensive release of favorable policies for the traditional Chinese medicine industry has led to a continuous sharp rise in the tuyere of the traditional Chinese medicine sector. In terms of news, recently, it is rumored that the wholly-owned subsidiary of Shanghai Kaikai Industry Company Limited(600272) Shanghai leiyunshang pharmaceutical West Co., Ltd. has a national confidential formula of traditional Chinese medicine Liushen Pill.
In the face of the continuous sharp rise in share prices, Shanghai Kaikai Industry Company Limited(600272) has issued announcements on abnormal fluctuations in stock trading and risk tips for many times.
On January 13, Shanghai Kaikai Industry Company Limited(600272) issued a risk warning announcement again, saying that the company did not have any national confidential pharmaceutical formula, nor did it have the production business of Liushen Pill. Recently, the company’s share price has increased greatly, so it is necessary to beware of the “drum beating and flower spreading” of hot money in the market, make rational decisions and pay attention to investment risks.
short term benefits of great health transformation
Insiders said that Shanghai Kaikai Industry Company Limited(600272) further promoting the transformation of big health strategy since last year has also attracted the attention of the capital market.
As for the business development, the company said that at present, there is no significant change in production and operation activities, the great health transformation needs a long cultivation period, and the investment income is difficult to show in the short term. If the transformation project is gradually promoted, it may have a certain negative impact on the company’s profits at the beginning of the project.
On January 5, Shanghai Kaikai Industry Company Limited(600272) released a performance forecast that the net profit attributable to the parent company in 2021 is expected to be between RMB 1982 million and RMB 22.56 million, with a year-on-year increase of 45% – 65%, and the expected earnings per share is RMB 0.08-0.09.
The announcement also said that during the reporting period, the company received a total of 12.9 million yuan of government subsidies. Shanghai Kaikai Industry Company Limited(600272) said that most of the pre increase in performance in 2021 came from non operating profits and losses. Expenditures similar to the special government subsidies and comprehensive reform costs occurred infrequently, which only affected the current net profit and did not have sustainability.
